Abstract:
본 발명은 카나비디올 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물을 제공한다. 본 발명의 신규한 카나바디올 유도체는 아세틸콜린에스테라제 저해 효능 및 부틸릴콜린에스테라제 저해 효능뿐만 아니라 모노아민 옥시다아제 B에 대한 저해 효능을 나타내는 것으로 확인되어, 치매 환자들에게서 나타나는 뇌조직 내의 아세틸콜린 수준 저하 및 혈중 부티릴콜린 수준 저하를 동시에 달성할 수 있고, 뇌세포 손상을 막음으로써 보다 효과적인 인지기능 개선 치료 효과를 기대할 수 있다. 따라서, 본 발명의 카나비디올 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 인지기능 개선용 조성물은 아세틸콜린에스테라제, 부티릴콜린에스테라제 및 모노아민 옥시다아제 B를 동시에 저해하는 물질로 의약 및 건강기능식품 분야에서 인지기능 개선 물질로서 유용하게 사용될 수 있다.
Abstract:
Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.
Abstract:
Organosulfur compounds of the general formula (2) are described, wherein R 1 and R 2 are linear or branched C1- C5 alkyl; linear or branched C1- C5 alkenyl with the proviso that R 1 is not prop-1-enyl (allyl); substituted linear or branched C1- C5 alkenyl or substituted linear or branched C1- C5 alkyl, in which the substituents are selected from OR 3 , NR 4 R 5 , COOR 6 , CONR 7 R 8 , in which R 3 is selected from H, COR 9 , para- methoxybenzyl and trialkylsilyl, in which R 9 is alkyl or substituted alkyl; R 4 and R 5 are alkyl or R 4 and R 5 together form a phthalimido group; R 6 is alkyl or substituted alkyl; and R 7 and R 8 are alkyl or substituted alkyl; substituted or unsubstituted aromatic specifically where R 1 and R 2 are benzyl, para -methoxybenzyl and/or ortho , para - methoxybenzyl and substituted or unsubstituted heteroaromatic. The compounds can be used for inhibiting the growth of tumour cells and for treating cancer. A pharmaceutical composition and a method of preparing the compounds are also described.
Abstract:
The instant invention relates to a composition comprising a) an organic material which is susceptible to oxidative, thermal or light-induced degra- dation, and b) at least one compound of the formula (I) wherein the general symbols are as defined in claim 1; especially wherein at least one of the radicals R 2 , R 3 or R 4 is is -CH 2 -CH(CH 3 )-S(O) p -R 12 , -CH 2 -CH 2 -CH 2 -S(O) p -R 12 , -CH 2 -CH(R 11 )-CH 2 -R 12 or -CH 2 -CH=CH-R 12 , R 11 is hydrogen or halogen, R 12 is a monovalent perfluorinated alkyl or alkenyl, linear or branched organic radical having four to twenty fully fluorinated carbon atoms; or -CH 2 CH 2 (CF 2 ) m CF 3 , m is 3 to 12, and p is 0, 1 or 2. The compounds of the formula I are useful as reducers of surface energy for organic mat- erials, for example synthetic polymer. Polymers with such a reduced surface energy possess an "easy-to-clean", "self-cleaning" "antisoiling", "soil-release" "antigraffiti", "oil resistance", "solvent resistance", "chemical resistance", "self lubricating", "scratch resistance", "low moi- sture absorption", "dirt pickup resistance", "slip properties" and "hydrophobic surface"; and anti-adhesion properties against proteins and against microorganism such as for example bacteria, fungi and algae.
Abstract:
Pesticidal 1,4-diaryl-2,3-difluoro-2-butene compounds of formula (I) wherein Ar is phenyl, 1- or 2-naphtyl or a 5- or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted; is C2-C6-alkenyl, C4-C6-cycloalkenyl or C1-C2-alkoxy-C2-C6-alkyl; and Ar1 is phenoxyphenyl, phenyl, biphenyl, phenoxypyridyl, benzylpyridyl, benzylphenyl, benzoylphenyl, 1- or 2-naphthyl, or a 5 or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted, intermediates and methods for the preparation of compounds of formula (I) and compositions and methods comprising the compounds and compositions for the control of insect and acarid pests.
Abstract:
A method for identifying molecules and designing novel pharmaceuticals is disclosed. The disclosed method of novel pharmaceutical design identifies a novel chemical group that triggers a mechanism of action for an identified reaction, thereby avoiding the various structural complexities associated with the application of the structure-based drug design. Additionally, examples of potential therapeutics identified by the mechanism based drug design method are provided.
Abstract:
This invention generally relates to nanocrystal compounds, and linker arm for nanocrystal compounds that attach the nanocrystals to the organic compounds. The nanocrystal compound comprises a nanocrystal, linker arm, and organic compound. Preferably, the organic compound is a biologically active compound that can provide a fluorescent sensor. Preferably, the linker arm is a carbon chain with an attachment point for the nanocrystal and an attachment point for the organic compound. Specifically, the nanocrystal is attached to the linker arm through a R3 group and the organic compound is attached to the linker arm through a R2 group. R2 is a bond or selected from the group consisting of carbonyl, O, NH, S, CONH, COO, S, C1-10 alkyl, carbamate, and thiocarbamate. R3 is selected from the group consisting of: SH, O(CH2(n)O)nSH, NH(CH2(n)O)nSH, NH(CH2(n)NH)SH, S(CH2(n)O)nSH, S(CH2(n)S)SH, anda polyether chain. n is 1-10. S is attached to the nanocrystal.
Abstract:
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in therapy and in the regulation of metabolism, especially lowering blood glucose levels. The compounds referred to are compounds according to the formula (I).